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Abstract
Background: Patients with Fanconi anemia (FA) suffer from multiple defects, most notably of the
hematological compartment (bone marrow failure), and susceptibility to cancer. Cells from FA
patients show increased spontaneous chromosomal damage, which is aggravated by exposure to
low concentrations of DNA cross-linking agents such as mitomycin C or cisplatin. Five of the
identified FA proteins form a nuclear core complex. However, the molecular function of these
proteins remains obscure.
Methods: Oligonucleotide microarrays were used to compare the expression of approximately
12,000 genes from FA cells with matched controls. Expression profiles were studied in
lymphoblastoid cell lines derived from three different FA patients, one from the FA-A and two from
the FA-C complementation groups. The isogenic control cell lines were obtained by either
transfecting the cells with vectors expressing the complementing cDNAs or by using a spontaneous
revertant cell line derived from the same patient. In addition, we analyzed expression profiles from
two cell line couples at several time points after a 1-hour pulse treatment with a discriminating dose
of cisplatin.
Results: Analysis of the expression profiles showed differences in expression of a number of genes,
many of which have unknown function or are difficult to relate to the FA defect. However, from a
selected number of proteins involved in cell cycle regulation, DNA repair and chromatin structure,
Western blot analysis showed that p21waf1/Cip1 was significantly upregulated after low dose cisplatin
treatment in FA cells specifically (as well as being expressed at elevated levels in untreated FA cells).
Conclusions: The observed increase in expression of p21waf1/Cip1 after treatment of FA cells with
crosslinkers suggests that the sustained elevated levels of p21waf1/Cip1 in untreated FA cells detected
by Western blot analysis likely reflect increased spontaneous damage in these cells.
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Background
The autosomal recessive disorder Fanconi anemia (FA) is
clinically characterized by bone marrow failure, predispo-
sition to cancer and various developmental abnormalities
[1]. FA is genetically heterogeneous, and thus far eight
complementation groups have been described. Six of the
identified FA genes (FANCA, -C, -D2, -E, -F, and -G; [2–8])
encode proteins that are unique and lack apparent homol-
ogy to other proteins or to each other. In addition, there
are no conserved motifs present in these FA proteins,
hampering understanding of their molecular function.
Recently, biallelic mutations were found in the BRCA2
gene in patients belonging to complementation groups
FA-D1 and one FA-B patient [9]. At the cellular level, FA is
characterized by increased spontaneous genomic instabil-
ity and hypersensitivity to DNA crosslinking agents, e.g.
cisplatin and mitomycin C (MMC) [reviewed in [1]]. Mul-
tiple studies have also shown defects in FA cells related to
the interferon-signaling pathway. Compared to control
cells, FA cells express constitutively high levels of ISGF3
gamma, IRF-1, p21waf1/Cip1 and MxA [10,11].
Studies on the FA proteins have shown that five FA pro-
teins, FANCA, FANCC, FANCE, FANCF, and FANCG, bind
to each other to form a nuclear core complex [Reviewed in
[12] and [13]]. FANCD2 is a nuclear protein that requires
activation by mono-ubiquitination. In mutant FA cells
that lack one of the FA core complex proteins, FANCD2 is
not activated by ubiquitination, suggesting that these FA
proteins exert a common molecular function in the nucle-
ar compartment of the cell [14]. Whether BRCA2 is in-
volved in the same pathway or exerts a separate function
is currently unknown [15].
Crosslinking agents are widely used for the treatment of
various types of cancer and are thought to exert their cyto-
toxic effect predominantly through irreversible binding
with DNA. How the FA proteins are related to this cytotox-
ic effect, e.g. by functioning in processes such as DNA re-
pair, cell cycle control or protection, is unknown. Upon
treatment with a discriminating dose of crosslinking agent
that will only transiently arrest the growth of wild type
cells, FA cells arrest in the late S or early G2-phase of the
cell cycle, and ultimately undergo cell death [16–21]. In
contrast to normal cells, FA cells fail to inhibit replicative
DNA synthesis after treatment with crosslinking agents.
While normal cells will arrest in S-phase, FA cells continue
replication and subsequently arrest at a later cell cycle
check point [22,23]. This hypersensitivity to crosslinking
agents is the hallmark of the FA phenotype.
Many studies have indicated that in vitro treatment of cells
with cisplatin affects the expression of specific genes in-
volved in various molecular processes such as transcrip-
tion, DNA repair, apoptosis, and cell cycle regulation.
Examples are induction of c-jun, c-fos, ercc1, gadd45,
gadd153, and p21waf1/Cip1 [24–28]. Some of these genes
respond within hours after treatment of cells, e.g. c-jun,
whereas others show maximum changes in expression af-
ter 24 to 72 hours, e.g. p21waf1/Cip1, gadd45 and gadd153.
Recently developed techniques, cDNA microarrays and ol-
igonucleotide expression probe arrays, enable the system-
atic analysis of expression of thousands of genes in a
single experiment [reviewed in [29]]. These techniques are
useful to evaluate possible differences in gene expression
profiles between FA and control cells, either at baseline or
after crosslinker treatment. To study this, there are a
number of experimental approaches to consider. For ex-
ample, one might compare FA cells with cells from
healthy controls. This might necessitate studying a large
number of both types of cells in order to reduce false pos-
itives due to genetic differences in the cell lines that are
unrelated to FA. Another approach would be to study cell
lines derived from FA patients that are compared with the
same cell lines corrected by transfection with the comple-
menting cDNA. The use of such isogenic cell lines would
presumably reduce the number of false positives and
therefore reduce the number of cell lines that need to be
studied. However, this might also result in a non-physio-
logic expression of the FA protein in transfected cells,
which might influence the expression profiles. Therefore,
we used the latter approach in combination with a unique
cell line couple, one FA-like cell line and one wild-type,
which are both derived from the same (mosaic) patient
[30]. This cell line couple has the advantage of being both
isogenic and expressing physiologic levels of the FA gene.
The aim of this study was to compare the expression pro-
files of FA cells defective in one of the FA core complex
proteins with isogenic control cells at baseline, as well as
in response to treatment with discriminating concentra-
tions of crosslinking agents. Differences in expression pro-
files of known genes might shed light on the cellular
function of the FA proteins.
Methods
Cell lines and cell culture
Lymphoblastoid cell lines that were used in this study are
derived from three individuals, one FA-A (HSC72) and
two FA-C (HSC536 and VU450) patients. The isogenic
control cell lines included an in vivo revertant cell line de-
rived from a mosaic patient, VU450R and the non-revert-
ed cell line VU450, or were derived by transfecting the
cells with either empty vector or with vectors expressing
the complementing cDNAs, HSC72 with pDR2 or pDR2-
FANCA-flag [31] and HSC536 with pDR2 or pDR2-flag-
FANCC [17]. The VU450R cell line is an ideal isogenic
control, since reversion by recombination resulted in en-
dogenous wild-type FANCC expression [30]. Cells wereBMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/5
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cultured at 37°C in 5% CO2 in RPMI1640 medium (Life
Technologies, Gaithersburg, MD) containing 10% new-
born calf serum (Hyclone Laboratories, Lorgan, UT) and
supplemented with 200 µg/ml hygromycin for transfected
cells.
Cisplatin treatment
Optimal discriminating doses of cisplatin (Pharmache-
mie b.v., NL) for each cell couple were determined using
growth inhibition tests [32,33]. Cells were pulse treated
for 1 hour with different concentrations (0, 0.2, 0.5, 1, 2,
5, 10, 20, and 50 µM) of cisplatin. Cells were subsequent-
ly washed and allowed to grow further until three cell di-
visions were reached in the untreated samples. For further
analysis, concentration of cisplatin was such that the high-
est differential effect between the FA and control cells was
obtained, i.e. growth inhibition of >50% in FA cells and
<10% in control cells: for the VU450 cell couple, 2.5 µM;
HSC536 cell couple, 1 µM; and HSC72 cell couple, 5 µM.
Approximately 108 cells were pulse treated with cisplatin
for one hour, washed and cultured further in separate por-
tions of 2.5 × 107 cells in fresh medium.
RNA isolation
Cells were harvested at various time points after treat-
ment. Total RNA was extracted using TRIzol LS reagent
(Life Technologies, Gaithersburg, MD) followed by a sec-
ond round of RNA purification using RNAeasy columns
(QIAGEN, Valencia, CA). Gene expression profiles were
determined from the three cell couples without treatment,
from the HSC72 cell couple 1, 3, 7 and 24 hours after cis-
platin treatment, and from the VU450 cell couple 1 and 7
hours after treatment.
Genechip expression analysis
Gene expression profiles were determined using the Hu-
man Genome U95A probe arrays (Affymetrix, Santa Clara,
CA) according to the manufacturer's protocol. These gene-
chips are oligonucleotide-based and represent ~12,000
human sequences that were previously characterized in
terms of function or disease association. Double stranded
cDNA was synthesized from each total RNA sample (10
µg) using T7-(dT)24 primer (GENSET Corp) and Super-
Script Choice system (Life Technologies, Rockville, MD).
From these cDNA samples, target samples were prepared
using in vitro cRNA transcription with biotinylated nucle-
oside triphosphates and BioArray High Yield RNA Tran-
script Labeling Kit (Enzo Diagnostics, Farmingdale, NY).
The cRNA samples were fragmented and hybridized to
U95A probe arrays. Scanning of the arrays was performed
with the HP Gene Array Scanner and data quantified using
Genechip Analysis Suite 3.3 (Affymetrix, Santa Clara, CA).
Data analysis
For analysis of the data, the data from all untreated cell
couples were combined and used as baseline for normali-
zation. All data sets were subsequently calculated relative
to the normalized data. Expression levels of beta-actin and
GAPDH (relative intensity) ranged between 0.8 – 1.2 in
all data sets. Genechip Analysis Suite 3.3 (Affymetrix, San-
ta Clara, CA) and GeneSpring 3.2.2 software (Silicon Ge-
netics, Redwood, CA) was used for analysis of the data. A
gene was considered as being up- or down-regulated only
if the average difference (AD) was > 10 (with target inten-
sity for scaling = 100) and if gene was called present.
Genes considered of potential interest were: genes >2-fold
up- or down-regulated in all pairs for non-treated samples
when comparing FA v control, and >3-fold up- or down-
regulated at any time point after cisplatin treatment in ei-
ther cell couple. A further selection from the latter set of
genes was made by scrutinizing for consistency in changes
of expression among cell line couples and in response to
cisplatin treatment (as indicated in table 2).
Immunoblotting
Protein extracts were prepared from cells as described pre-
viously [34]. Protein concentration in the extracts was de-
termined using a Bio-Rad Protein Assay (Hercules, CA),
and 10 µg protein was loaded on SDS-polyacrylamide
gels. Gels were transferred to Immobilon-P membrane
(MILLIPORE, Bedford, MA) and blocked in TBST with ei-
ther 5% dry milk or 5% BSA for 1 hour at room tempera-
ture. Incubation with primary antibody was according to
the manufacturer's protocols. The following primary anti-
bodies were used for immunoblotting: mouse anti-p300
(NM-11) and rabbit anti-p21waf1/Cip1 (Zymed Laborato-
ries, San Francisco, CA), mouse anti-CDC25a (abcam,
UK), mouse anti-PMS2 (E-19), rabbit anti-RGS2, rabbit
anti-BAF170 (Santa Cruz Biotechnology, Santa Cruz, CA),
mouse anti-p16 (G175-405; PharMingen), and mouse
anti-β-tubulin (Boehringer Mannheim).
Results
Expression analysis of untreated cells
Expression data from three different cell line couples, FA
cell lines (HSC72, HS536, and VU450) and their isogenic
controls (HSC72 + FANCA, HSC536 + FANCC, and
VU450 revertant), were analyzed. In addition, for two cell
line couples (HSC72 and VU450), expression profiles
were determined after treatment with discriminating con-
centrations of cisplatin. In general, approximately half of
the genes present on the probe arrays were identified as
being expressed in the lymphoblastoid cell lines. Some
low abundant mRNAs were not detected, as evidenced by
the fact that of the four FA genes present on the arrays
(FANCA, FANCC, FANCD2 and FANCG), only one (FAN-
CG) was detected, in both FA and control cell lines.BMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/5
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As shown in Table 1, comparison of the expression pro-
files from the three FA cell lines and their isogenic controls
showed that 10 genes were identified as being more than
2-fold differentially expressed in all cell couples. Although
we can not exclude that some of these genes may have a
physiological effect, many of the genes in Table 1 are dif-
ficult to relate to the molecular defect in FA cells, i.e. ge-
nomic instability and cross linker sensitivity. There is still
a reasonable chance that the majority of these genes were
obtained by chance since only three cell line couples were
used. Therefore, we further analyzed those most likely to
be related to the FA phenotype, i.e. p300 and p16 that are
involved in cell cycle regulation. However, comparison of
protein expression by Western blotting showed no con-
sistent differences in either p16 or p300 protein levels
(Figure 1).
Expression analysis of cisplatin-treated cells
To test the possibility that the hypersensitivity of FA cells
to crosslinking agents is reflected by a differential re-
sponse at the level of gene expression, we first determined
the concentration of cisplatin that best discriminated be-
tween the FA and control cell line couples. These concen-
trations were 2.5 µM and 5 µM cisplatin for the VU450
and HSC72 cell couples, respectively (Figure 2 and data
not shown).
Using specific criteria for differences in response (see
methods section), analysis of the expression profiles from
untreated versus 1 and 7 hours after cisplatin treatment
for the VU450 cell couple and from untreated versus 1, 3,
7, and 24 hours after treatment for the HSC72 cell couple,
resulted in 59 genes that were initially identified (Table
2). The selection criteria were mild, in order to avoid loss
of interesting data, thus increasing the risk of identifying
genes by chance. This is reflected by the facts that many
genes do not show a clear pattern of response to cisplatin
treatment and that all genes are in the low intensity range.
However, some of the genes in Table 2 are of possible in-
terest in the context of FA and crosslinker treatment, par-
ticularly those involved in cell cycle regulation (cdc25A
and RGS2), DNA repair (PMS2), and chromatin structure
(BAF170). Unfortunately, protein expression analysis us-
Table 1: Differentially expressed genes in untreated FA cells.
Description GenBank accession no. Fold change
Up regulated in FA cells VU450 HSC536 HSC72
- GLUT1 C-terminal binding protein, GIPC AF089816 5 2 17
- homeo box B7, HOXB7 M16937 5 61 3
- plasma glutamate carboxypeptidase, PGCP W29330 5 3 2
- proteinase inhibitor, SERPINB7 U71364 7 2 6
- E1A binding protein p300, EP300 U01877 2 2 2
Down regulated in FA cells
- selectin L, SELL M25280 2 16 5
- small inducible cytokine A4, SCYA4 J04130 2 3 41
- TXK tyrosine kinase, TXK L27071 10 3 3
- solute carrier family 16, SCL16A5 U59299 2 2 2
- cyclin-dependent kinase inhibitor 2A, p16 U26727 2 203 5
Figure 1
p16 and p300 protein expression in FA and control
cell lysates.10 µg protein from indicated cell extracts were
immunoblotted with p16, β-tubulin, and p300 specific anti-
bodies, as indicated. Extracts w e r e  f r o m  H S C 5 3 6  s t a b l y
transfected with empty vector (p; lanes 1) or with vector
expressing FANCC (C; lanes 2), and from HSC72 stably trans-
fected with vector expressing FANCA (A; lanes 3) or with
empty vector (p; lanes 4). β-tubulin was used as additional
loading control.
p16
p A
HSC536
C
HSC72
p300
p
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Table 2: Differentially expressed genes between FA and control cells after cisplatin treatment.
Gene Description GenBank accession no. Change*
Membrane protein
C-type lectin, AICL X96719 Up 1 h in WT
Integral membrane protein, LIG-1 W25875 Up 1 h in FA
Integral membrane protein, SIGMAR1 U79528 NC
Growth factor
Insulin growth factor binding protein 2, IGFBP-2 S37730 NC
Endothelial cell growth factor, platelet-derived, ECGF1 M63193 Down 24 h in WT
IL18R1/IL-1RRP U43672 NC
BMP-4 U43842 Down 1 h in FA
IL10R U00672 NC
Notch ligand, JAGL1 AF003837 NC
Signal transduction
Adapter molecule in signal transduction, DOC1 U53445 Up 24 h in FA
SRC family tyrosine kinase, FYN M14333 Down 24 h in FA
Protein tyrosine phosphatase, PTPG U46116 Down >7 h in FA
Regulator of G-protein signaling, G0S8/RGS L13463 Up 1 h in FA
Regulator of G-protein signaling, GIPC/RGS19IP1 AF089816 Up 24 h in WT
Mitogen-activated protein kinase kinase kinase kinase 4, MAP4K4 AB014587 NC
Serine/threonine kinase, KIAA0623 AB014523 NC
Related to the N-terminus of TRE, RNTRE D13644 NC
Related to intracellular calcium signaling, HOMER-1B Y17829 NC
MEK6/MKK6 U39657 NC
Zinc finger protein, LOC58500 X16282 NC
LYT10/NF-kB2 U20816 NC
Dual specific tyrosine kinase, DYRK2 Y13493 NC
Phospholipase C beta 2, PLCB2 M95678 NC
Containing Pleckstrin homology domain, KIAA0763 AB18306 NC
Vesicular Rab-GAP/TBC-containing protein, AD3 AB024057 NC
Calcium-binding protein, S100C/Calgizzarin D38583 NC
Transcription factor
Transcript homolog, MEST/PEG1 D78611 NC
Myotubularin related protein 2, MTMR2 AB028996 NC
Homeobox protein related to skeletal development, MSX1 M97676 NC
Transcription factor, MRG1 U65093 NC
Homeobox, PRH/PRHX L16499 NC
MSX2/MSH/HOX8 D89377 NC
Transcriptin activating factor, CREBP L05515 NC
Transcription coactivator, TCFEC/TFECL D43945 NC
Putative transcription regulator, CARM-1 AI660225 Down 7 h in FA
Cell cycle
CDC25A M81933 NC
Apoptosis
Similar to rat CIPHAR-1, DKFZp564O0823 AL080121 NC
BCLX Z23115 NC
Protease inhibitor, PLANH2/PAI2 Y00630 NC
Vanin-2, VNN2 D89974 Down 24 h in WT
DNA repair/Chromosome regulator
Similar to DNA helicase, FLJ10738 W28620 NC
HPARG AF005043 NC
BAF170 U66616 NC
PMS2 U13696 NC
Intracellular processing
Ubiquitin protein ligase, E6-AP AF002224 Up >1 h in WT
Putative splicing factor, DOM3Z AF059252 Down >7 h in FA
CBP2/TAFI M75106 NC
Uronyl 2-sufotransferase AB020316 NC
Miscellaneous
Procollagen-proline, 2-oxoglutarate 4-dioxygenase, P4HA2 U90441 NCBMC Blood Disorders 2002, 2 http://www.biomedcentral.com/1471-2326/2/5
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ing Western blotting did not confirm any consistent
changes in protein expression after cisplatin treatment
(Figure 3A).
Of the genes with relatively high signal intensities, the cell
cycle inhibitor p21waf1/Cip1  was increased in FA cells
(HSC72) 24 hours after treatment but not in control cells
(HSC72 + FANCA). However, this increase was < 2-fold
and therefore excluded in the initial analysis. Western blot
analysis of p21waf1/Cip1  protein expression showed a
strong increase in FA cells at 24 hours after cisplatin treat-
ment, while p21waf1/Cip1 was only slightly increased in the
corrected cells (Figure 3B). In addition, p21waf1/Cip1 ap-
peared to be somewhat higher expressed in FA cells even
without treatment, which was not observed in the expres-
sion array analysis.
Discussion
The FA proteins have a caretaker function and a defective
FA pathway results in chromosomal instability, a pheno-
type that is aggravated by exposure of cells to cross-linking
agents [1]. Here we have tried to identify differences in
gene expression between FA and control cells that might
shed light on the molecular role of the FA proteins. Al-
though recent findings of BRCA2 mutations in a subset of
FA patients and studies on the FANCD2 protein suggests
a link between the FA pathway, BRCA1, and DNA repair
[9,14], the exact function of the FA core complex remains
elusive.
We examined samples using oligonucleotide arrays har-
boring probes directed to approximately 12,000 different
transcripts. Various types of crosslinking agents are used
in FA research, such as mitomycin C, diepoxybutane, pso-
ralen with UV, and cisplatin [1]. In the present study, we
used cisplatin because the effect of this agent on gene ex-
pression has been well described and there is no need for
metabolic activation of the drug (unlike mitomycin C).
Relatively late effects, such as cell cycle arrest and apopto-
sis, have been documented for FA [16–23]. Our main in-
terest, however, was to determine the effect on early
response genes that preceded cell cycle arrest. Therefore,
cells were pulse treated for one hour with cisplatin and
samples taken shortly thereafter. The concentration of cis-
platin used was chosen to achieve the highest discrimina-
tion between FA and control cells in growth inhibition
assays. Although this cytotoxic dosage is relatively low
compared to those used in prior studies of cisplatin-in-
duced gene expression changes, we reasoned that a higher
dosage would lead to indiscriminate growth inhibition in
both FA and control cells [17,18,20]. In addition, these
concentrations were found to be sufficient for inactivating
tyrosine phosphorylation of CDC2, 24 hours post treat-
ment, as assessed by Western blotting (data not shown).
The profiling analysis revealed differences in expression of
a number of genes, many of which are difficult to relate to
Unknown, FLJ21174 AA149307 NC
Unknown, expressed in macrophage X89059 Up >1 h FA
Clathrin light chain b X81637 NC
Related to lipodystrophy, LPIN2 D87436 NC
ME1 U43944 NC
Unknown, KIAA0090 D42044 Down 24 h in WT
Unknown, DKFZp564I122 AL080062 NC
Unknown, KIAA0241 D87682 NC
* NC indicates that the observed changes were not consistent. When consistent changes were observed indicated are up or down regulation, fol-
lowed by time point(s) after treatment at which changes of expression were observed, and cell type; WT indicates observed in corrected cells, FA 
indicates observed in FA cells.
Table 2: Differentially expressed genes between FA and control cells after cisplatin treatment. (Continued)
Figure 2
Cisplatin induced growth inhibition. VU450 cell lines
were one hour pulse treated with indicated concentrations
of cisplatin. Dotted line indicates the dosage used for gene
expression experiments. VU450R; reverted (crosslinker
resistant) cell line and VU450; FA (crosslinker sensitive) cell
line.
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the FA pathway or are unlikely to be expressed in B-lym-
phocytes. Only a few genes are related to processes that are
possibly linked to the FA defect, such as those involved in
cell cycle regulation, chromatin structure, and DNA mis-
match repair. However, using Western blot analysis with
antibodies directed to the respective gene products, we
were unable to confirm differences in protein levels for all
these genes. Genes that previously have been shown to re-
spond to cisplatin and that were present on the arrays, i.e.
c-jun, c-fos, ercc1, gadd153, gadd45, pcna and p21waf1/
Cip1, were not changed under the conditions used, except
for an increase in expression of p21waf1/Cip1. Although the
change in our experiments was < 2-fold, there was a clear
induction of p21waf1/Cip1 expression in FA cells 24 hours
post treatment that was not seen in the control cells.
Microarray based experiments to discover cisplatin in-
duced differences in gene expression have been performed
previously both using cell lines [35] and tissues from rats
[36]. These experiments are however difficult to relate to
our experiment due to much longer exposure time to sim-
ilar concentrations of cisplatin used [35] or due to the dif-
ferences in experimental approach [36]. Although in
those experiments many genes were found to be differen-
tially expressed, also p21waf1/Cip1 was found to be induced
by cisplatin treatment. The reason for not detecting other
cisplatin-induced genes in our experiments might be the
relatively low concentrations of cisplatin used. This sug-
gests that p21waf1/Cip1 (compared to other genes) regula-
tion is very sensitive to cisplatin, at least in
lymphoblastoid FA cells. p21waf1/Cip1 is known to be a key
regulator of G1 cell cycle arrest, but has more recently also
been implicated in G2 cell cycle regulation [37]. This ob-
servation fits well with the previously observed upregula-
tion of p53 and cyclin B proteins, inactivation of CDC2,
and cell cycle arrest that follows exposure to low doses of
cross-linking agents [17–19].
Earlier studies reported that FA lymphoblasts express in-
creased levels of transcripts from genes connected to the
interferon pathway, IRF-1 and MxA [10,11]. Although the
approaches used were different, these observations are not
confirmed by our data. Both genes were detected as being
expressed but showed no significant differences between
FA and controls. In addition, the constitutive elevated ex-
pression of p21waf1/Cip1 observed in FA cells [9] was not
found at the level of mRNA in our experiments. However,
we did observe a slight increased expression of p21waf1/
Cip1 protein in FA cells. This might be explained by post-
Figure 3
Protein expression in FA and control cells treated with cisplatin. 10 µg protein from indicated cell extracts were
immunoblotted with specific antibodies directed against indicated proteins; A) BAF170, CDC25a, PMS2, RGS2 and β-tubulin;
B) p21waf1/Cip1. Extracts were from HSC72 and HSC536 cells transfected with empty vector or with vector expressing correct-
ing cDNA as indicated. Cells were one hour pulse treated with discriminating concentrations of cisplatin; HSC72 with 5 µM
and HSC536 with 1 µM. β-tubulin was used as additional loading control.
A
-       +3     +8    +24     -      +3     +8    +24 -       +3     +8    +24     -      +3     +8    +24
B
βTUB
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transcriptional regulation of p21waf1/Cip1 or by a relatively
low sensitivity of the expression arrays, incapable of de-
tecting minor increases in mRNA. Interestingly, the ob-
served elevated levels of p21waf1/Cip1 expression in FA cells
is reminiscent of a number of other DNA repair defective
cell types, i.e. those defective in ATM, ERCC1, BRCA1, and
BRCA2 [38–42].
Except for p21waf1/Cip1, these experiments did not reveal
differences in gene expression that could explain the basic
defect in FA, when looking at baseline or when looking for
genes that preceded cisplatin-induced cell cycle changes.
There are several possible explanations possible for this.
First, no significant changes at the transcriptional level are
present in FA cells. It might well be that phenotypic differ-
ences of FA cells are predominantly reflected at the post-
translational level. The recent finding of FANCD2 mono-
ubiquitination suggests that regulation by protein modifi-
cation is an important step in the FA pathway [14]. Sec-
ond, subtle changes in gene expression might remain
undetected. The up- or down-regulation of an entire func-
tional pathway may have large effects but be difficult to
trace using these types of experiments, particularly when
our knowledge of components involved in the various
functional pathways is limited. Third, expression of cer-
tain genes may be different but not detected either be-
cause of lack of sensitivity or absence of the
oligonucleotide sequence for those specific genes in the
arrays used. Concerning sensitivity, it might be that the re-
sponse of cells to cross-linker damage is related to signals
at a certain stage of the cell cycle (e.g. during replication),
resulting in a dilution of the response when using an asyn-
chronous population of cells. The p21waf1/Cip1  results
showed that differences in expression of transcripts with
high intensity on the arrays were detected even though
this was a single data point and the difference was < 2-
fold. Therefore, differences < 2-fold in genes with low in-
tensity signals are presumably present but missed because
of the increasing levels of noise in that region of intensity,
making it difficult to discriminate between true and false
positives in a limited number of samples.
Conclusions
Analysis of the expression data resulted in the identifica-
tion of 10 genes (Table 1) that were found to be consist-
ently differentially expressed between FA and control
cells, as well as 59 genes (Table 2) that exhibited different
response patterns between FA and control cells after treat-
ment with cisplatin. However, subsequent analysis of se-
lected genes at the protein level by Western blot analysis
did not confirm the observed differences in expression.
Several limitations of the experimental approach were dis-
cussed that might explain these results.
The observed strong cisplatin-induction of p21waf1/Cip1 in
FA cells, but not in control cells, suggests that FA cells re-
spond similarly as non-FA cells but in a hypersensitive
manner. According to experiments from other investiga-
tors [20] cell cycle checkpoints function properly, suggest-
ing that cross-linking agents evoke more damage or create
damage that remains unrepaired in cells with a defective
FA pathway. Therefore, the observed increase in basal
p21waf1/Cip1 levels in FA cells by Western blot analysis
most likely reflects a physiologic response to the presence
of spontaneous damage in a subpopulation of these cells.
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